Granite Investment Partners LLC Buys Shares of 72,653 Aratana Therapeutics Inc (NASDAQ:PETX)

Granite Investment Partners LLC purchased a new position in shares of Aratana Therapeutics Inc (NASDAQ:PETX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 72,653 shares of the biopharmaceutical company’s stock, valued at approximately $382,000. Granite Investment Partners LLC owned approximately 0.17% of Aratana Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Voya Investment Management LLC raised its position in Aratana Therapeutics by 22.7% in the 2nd quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 3,610 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Aratana Therapeutics by 7.2% during the 2nd quarter. ProShare Advisors LLC now owns 25,322 shares of the biopharmaceutical company’s stock valued at $183,000 after purchasing an additional 1,709 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in shares of Aratana Therapeutics by 6.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 30,127 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 1,875 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Aratana Therapeutics by 25.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,176 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 6,898 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Aratana Therapeutics by 16.4% during the 2nd quarter. Rhumbline Advisers now owns 48,214 shares of the biopharmaceutical company’s stock valued at $349,000 after purchasing an additional 6,800 shares during the last quarter. 73.53% of the stock is currently owned by hedge funds and other institutional investors.

In other Aratana Therapeutics news, insider Craig A. Tooman sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $5.27, for a total value of $158,100.00. Following the completion of the transaction, the insider now directly owns 75,024 shares in the company, valued at approximately $395,376.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Peter Steven St sold 19,367 shares of the company’s stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $4.77, for a total value of $92,380.59. Following the completion of the transaction, the chief executive officer now owns 672,259 shares of the company’s stock, valued at $3,206,675.43. The disclosure for this sale can be found here. Insiders sold a total of 1,056,399 shares of company stock valued at $6,087,271 over the last 90 days. 5.20% of the stock is currently owned by corporate insiders.

Aratana Therapeutics Inc (NASDAQ:PETX) traded down $0.27 during trading on Friday, reaching $4.10. 549,703 shares of the company traded hands, compared to its average volume of 422,226. Aratana Therapeutics Inc has a one year low of $3.91 and a one year high of $7.67. The company has a quick ratio of 3.08, a current ratio of 3.42 and a debt-to-equity ratio of 0.26.

Several equities research analysts have recently commented on the stock. Stifel Nicolaus reaffirmed a “hold” rating and set a $6.00 price target on shares of Aratana Therapeutics in a research report on Monday, December 18th. HC Wainwright set a $10.00 target price on shares of Aratana Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 21st. Zacks Investment Research lowered shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 18th. Jefferies Group reissued a “buy” rating and issued a $8.00 target price on shares of Aratana Therapeutics in a report on Friday, November 3rd. Finally, ValuEngine lowered shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $8.55.

TRADEMARK VIOLATION WARNING: “Granite Investment Partners LLC Buys Shares of 72,653 Aratana Therapeutics Inc (NASDAQ:PETX)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/11/granite-investment-partners-llc-buys-new-holdings-in-aratana-therapeutics-inc-petx.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply